Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART: Golimumab Device Preference in Ulcerative Colitis
NCT02155335Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2014
- Primary completion
- Oct 2015
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 4 trial of golimumab in ulcerative colitis (UC), sponsored by Merck & Co.. Started Jul 2014; status: completed.
02
Drugs
golimumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02155335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02155335.